Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Inclusion Criteria:

* One of the following diagnoses with histological confirmation by the Pathology Department at H. Lee Moffitt Cancer Center:
* Acute Lymphocytic Leukemia (ALL) in complete remission 1 (CR1) with t(9:22) or t(4:11), or any ALL beyond CR1
* Acute Myelogenous Leukemia (AML) with high risk cytogenetics in CR1 as defined by Bloomfield any AML beyond CR1
* Myelodysplastic Syndrome (MDS) with International Prognostic Scoring System (IPSS) score \> 1
* Chronic myelomonocytic leukemia (CMML)
* Chronic Myelogenous Leukemia (CML) with Imatinib-refractory chronic phase, or beyond chronic phase by morphology or cytogenetics
* Myelofibrosis
* Severe aplastic anemia
* Chemosensitive Non-Hodgkin's lymphoma and Hodgkin's disease that are not candidate to autologous transplant due to prior autologous transplantation
* Multiple Myeloma patient not candidate for autologous stem cell transplantation
* Karnofsky performance status ≥ 70% (adult)
* Normal organ and marrow function as defined below:
* Hepatic: Total bilirubin must be less than or equal to 2mg/dL (Gilbert and other syndromes with increased indirect bilirubin are allowed); serum transaminases must be less than two times the upper limit of normal
* Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) (corrected for Hgb), forced expiratory volume-one second (FEV1), forced vital capacity (FVC) must be greater than 50% predicted
* Cardiac: Left ventricular ejection fraction at rest must be greater than 50%
* Renal: Creatinine clearance (measured or calculated) must be equal or greater than 50 ml/min/1.73m\^2

Exclusion Criteria:

* Anti thymocyte globulin (ATG) or anti T cell therapy in prior 45 days
* Splenectomized patients;
* A positive pregnancy test administered to all females of childbearing potential prior to allogeneic stem cell transplant
* Inability to comply with follow up as determined by the patient's physician
* HIV-I/II infection prior to hematopoietic stem cell (HSC) transplantation, confirmed by nucleic acid test (NAT)
* Uncontrolled bacterial or fungal infection
* History of documented invasive aspergillosis or cytomegalovirus (CMV) pneumonia
* Presence of any of the following comorbid conditions:
* History of myocardial infarction
* Congestive heart failure (even if symptomatically controlled)
* Peripheral vascular disease (including intermittent claudication or history of bypass for arterial insufficiency)
* Untreated thoracic or abdominal aneurysm (6cm or more)
* History of any cerebrovascular accident including transient ischemic attacks
* Dementia
* History of peptic ulcer disease requiring treatment
* Connective tissue/rheumatologic disorders
* Diabetes unless being managed with dietary changes only
* Hemiplegia/paraplegia
* History of solid tumor excluding skin or cervical carcinoma after curative resection